FY2025 EPS Estimate for Larimar Therapeutics Cut by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Analysts at HC Wainwright lowered their FY2025 earnings per share estimates for Larimar Therapeutics in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($1.91) for the year, down from their previous forecast of ($1.77). HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($2.10) EPS.

LRMR has been the topic of a number of other reports. Guggenheim restated a “buy” rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday. Robert W. Baird decreased their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Truist Financial initiated coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price target for the company. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Trading Up 5.6 %

Shares of LRMR opened at $2.38 on Thursday. The stock’s 50 day moving average is $3.10 and its two-hundred day moving average is $5.16. Larimar Therapeutics has a twelve month low of $2.19 and a twelve month high of $11.20. The firm has a market capitalization of $151.54 million, a PE ratio of -2.07 and a beta of 0.99.

Larimar Therapeutics (NASDAQ:LRMR) last issued its earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Institutional Investors Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Fi3 FINANCIAL ADVISORS LLC increased its holdings in Larimar Therapeutics by 16.7% during the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company’s stock valued at $92,000 after acquiring an additional 3,411 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Larimar Therapeutics by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock worth $143,000 after purchasing an additional 3,425 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Larimar Therapeutics by 21.9% during the 3rd quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock worth $143,000 after purchasing an additional 3,549 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Larimar Therapeutics by 12.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company’s stock valued at $137,000 after buying an additional 3,877 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Larimar Therapeutics by 8.1% during the fourth quarter. Bank of America Corp DE now owns 53,190 shares of the company’s stock worth $206,000 after buying an additional 3,980 shares in the last quarter. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.